Kornimate/medical-research-clean huggingface dataset:
long-term outcomes in the treatment of infantile and acquired esotropia with botulinum toxin

Conditions: Esotropia

Summary: to investigate long-term treatment outcomes of patients receiving botulinum toxin a therapy for infantile and acquired esotropia.

participants: 164 patients with infantile esotropia and 89 patients with acquired esotropia. methods: patients were injected with botulinum toxin into two medial rectus muscles and followed from 1992 to 2005. patients were evaluated at 1 week, 2, 6 and 12 months, and then yearly post-injection. main outcome measures: degree of motor alignment, recurrence rate, incidence of stereopsis, and dissociated vertical deviation along with complications.

Eligibility criteria:
inclusion criteria: * infantile esotropia and acquired esotropia exclusion criteria: * exotropia, high ac/a ratio accommodative esotropia, patients with neurological deficit including cerebral palsy, down syndrome and mental retardation, and ocular anomalies including retinopathy of prematurity. patients lost to follow-up at 6 months or less after the last injection were also excluded.

Keywords: botulinum esotropia
sevoflurane in electroconvulsive therapy

Conditions: ECT; Anesthesia

Summary: the purpose of the study was to investigate the effects of different doses of sevoflurane used in electroconvulsive therapy (ect) on duration of seizure, hemodynamic response and recovery profiles

motor (emg) and electroencephalography seizure duration (eeg), heart rate (hr) and mean arterial pressure (map) values, and recovery times were recorded.

Eligibility criteria:
inclusion criteria: * study included 25 patients of american society of anesthesiologists (asa) physical status i-ii aged between 18-60 years who were scheduled for ect sessions under general anesthesia exclusion criteria: * pregnancy * cerebrovascular disease * epilepsy * unstable cardiovascular disease * chronic obstructive pulmonary disease; and * renal or hepatic failure

Keywords: electroconvulsive therapy seizures sevoflurane
study of alln-177 in patients aged 12 years or older with enteric or primary hyperoxaluria and hyperoxalemia

Conditions: Enteric Hyperoxaluria; Primary Hyperoxaluria; Hyperoxalemia

Summary: evaluate the efficacy and safety of alln-177 in reducing plasma and urinary oxalate levels in adult and pediatric patients with enteric hyperoxaluria and hyperoxalemia or primary hyperoxaluria

phase 2, multi-center, open label, single arm study to evaluate the effect and safety of alln-177 in adult and pediatric patients aged 12 and older with enteric hyperoxaluria and hyperoxalemia or primary hyperoxaluria . approximately 15-20 evaluable subjects are planned to be enrolled in the study. eligible subjects will administer alln-177 with each meal/snack 5 times per day for 12 consecutive weeks.

Eligibility criteria:
inclusion criteria: 1. signed a informed consent form or an assent 2. aged 12 or older with body weight ≥ 35kg 3. history of primary hyperoxaluria or enteric hyperoxaluria associated with a known underlying enteric disorder associated with malabsorption (e.g., bariatric surgery, crohn's disease, short bowel syndrome, or other malabsorption syndrome) 4. urinary oxalate ≥ 40mg/24h (normalized for body surface area in children) at screening in patients with egfr \>15 ml/min/1.73m2 5. in patients with enteric hyperoxaluria, egfr \< 45ml/min/1.73m2 at screening 6. in patients with enteric hyperoxaluria, plasma oxalate \> 5µmol/l at screening 7. patients on dialysis, must be stable for greater than 3 months exclusion criteria: 1. unable or unwilling to discontinue vitamin c supplementation

Keywords: oxalate kidney stones oxalate nephropathy systemic oxalosis
dmt210 topical gel in the treatment of acne rosacea

Conditions: Acne Rosacea

Summary: the study evaluates the safety, tolerability, and efficacy of dmt210 gel, 5% when applied twice daily for 12 weeks in adult patients with moderate to severe acne rosacea. half of participants will receive dmt210 gel while the other half will receive vehicle control.


Eligibility criteria:
inclusion criteria: * patient is male or non-pregnant female at least 18 years of age. * clinical diagnosis of moderate to severe facial rosacea as determined by investigator's global assessment (iga) at randomization * patient has at least ten inflammatory lesions of rosacea on the face at randomization * patient is willing to apply the investigational product as directed * patient is willing and able to comply with the protocol exclusion criteria: * patient is pregnant or planning to become pregnant * patient is taking a topical therapy which may affect the patient's rosacea

Keywords: skin diseases rosacea
predicting operational difficulties and outcomes of rarp based on preoperative assessment - introducing the piodo questionnaire

Conditions: Prostate Cancer; Robot-Assisted Laparoscopic Radical Prostatectomy

Summary: the goal of this observational study is to learn about the factors that affect the course of robot-assisted radical prostatectomy and have an impact on functional and oncological outcomes in patients undergoing rarp. the main question it aims to answer is: • can the investigators predict the occurrence of operational difficulties and outcomes of rarp based on preoperative assessment including body habitus and pelvimetry? participants undergoing rarp will be assessed preoperatively with the use of a piodo questionnaire, a structured protocol of preoperative assessment focusing on clinical data and mri pelvic measurements to evaluate if the investigators can predict the risk of operational difficulties and possible outcomes of rarp. in a 1 year follow-up the investigators will collect data on functional and oncological outcomes.

various factors affect the course of rarp and have an impact on functional and oncological outcomes. to date, no structured protocol has been developed for the preoperative assessment of patients undergoing rarp that evaluates not only clinical data on the prostate cancer, but also patient characteristics, including anthropometric measurements of the pelvis. based on our previous research and preliminary study, the investigators have developed a piodo questionnaire to assess these factors and verify whether it is possible to predict the occurrence of operative difficulties as well as functional and oncological outcomes. participants undergoing rarp will be assessed preoperatively using the piodo questionnaire. the investigators will collect medical data and pelvic mri measurements to evaluate if the investigators can predict the risk of operational difficulties and possible outcomes of rarp. in a 1-year follow-up, the investigators will obtain information on potency and continence, as well as the presence of biochemical recurrence. achieving our goal will allow us to facilitate counselling of patients on their relative likelihood of post-operative continence or erectile function based on individual factors and anthropometric measurements and allow urologists to predict operative difficulties they may face during surgery.

Eligibility criteria:
inclusion criteria: * patients with prostate cancer undergoing rarp. exclusion criteria: * neoadjuvant androgen deprivation therapy before rarp. * lack of consent for study participation or willingness to comply with all procedures and assessments.

Keywords: prostate cancer rarp robot-assisted radical prostatectomy preoperative assessment pelvimetry magnetic resonance imaging
retrospective evaluation of clinical and radiographic outcomes following total talus replacement

Conditions: Talus; Ankle Arthropathy

Summary: this study is a retrospective analysis of patients who underwent surgery using a total talus replacement (ttr) implant with or without concurrent total ankle replacement and/or subtalar fusion. this study seeks to analyze the clinical and radiographic outcomes of ttr implant recipients and generate additional data on the safety and benefit of the ttr implant.


Eligibility criteria:
inclusion criteria: * \>18 years of age * patient underwent surgery involving a total talus replacement implant between 1/1/2019 and 01/28/2022. exclusion criteria: * no available postoperative data

Keywords: retrospective study ankle joint talus arthrodesis printing, three-dimensional joint prosthesis prosthesis design
transcranial direct current stimulation (tdcs) neuromodulation of executive function across neuropsychiatric populations

Conditions: Traumatic Brain Injury; Major Depressive Disorder; Bipolar Disorder; Schizophrenia; Attention Deficit Hyperactivity Disorder; Borderline Personality Disorder; Substance Use Disorders

Summary: in the current study, the investigators aim to understand the role of transcranial direct current stimulation (tdcs) in improving executive function across neuropsychiatric populations known to have deficits in this cognitive domain.

in the current study, the investigators aim to understand the role of transcranial direct current stimulation (tdcs) in improving executive function across neuropsychiatric populations known to have deficits in this cognitive domain. the investigators will select 8 relevant diagnostic categories: traumatic brain injury, major depressive disorder, bipolar disorder, schizophrenia, attention deficit hyperactivity disorder, borderline personality disorder and substance use disorder. the study will also include a cohort of healthy controls for comparison.

Eligibility criteria:
inclusion criteria 1. male and female outpatients 18-65 years of age 2. a diagnosis of traumatic brain injury, major depressive disorder, bipolar disorder, schizophrenia, attention deficit hyperactivity disorder, borderline personality disorder and substance use disorders meeting the diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) criteria. exclusion criteria 1. contraindication to tdcs: history or epilepsy, metallic implants in the head and neck, brain stimulators, vagus nerve stimulators, shunts, pacemakers, pregnancy. 2. active substance dependence (except for tobacco and cannabis). 3. pregnant or nursing females. 4. inability to participate in testing procedures. 5. additional exclusion criteria for healthy controls: 1. diagnosis of psychiatric of neurological disorder 2. ongoing treatment with any psychotropic medications.

Keywords: transcranial direct current stimulation executive function
a study to evaluate the efficacy and safety of jnj-77242113 (icotrokinra) in biologic-naïve participants with active psoriatic arthritis

Conditions: Arthritis, Psoriatic

Summary: the purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (psa) by assessing the reduction in signs and symptoms of psa.


Eligibility criteria:
inclusion criteria: * have a diagnosis of psoriatic arthritis (psa) for at least 3 months before the first administration of study intervention and meet classification criteria for psoriatic arthritis (caspar) at screening * have active psa as defined by: (a) at least 3 swollen joints and at least 3 tender joints at screening and at baseline (b) c-reactive protein (crp) greater than or equal to (\>=) 0.1 milligrams per deciliter (mg/dl) at screening from the central laboratory * have at least 1 of the psa subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis * have active plaque psoriasis with at least one psoriatic plaque of \>= 2 cm diameter or nail changes consistent with psoriasis * a female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (beta-hcg) at screening and a negative urine pregnancy test at week 0 prior to administration of study intervention exclusion criteria: * has previously received any biologic disease-modifying antirheumatic drugs (dmards) for psa or psoriasis * has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic (with the exception of psa), psychiatric, genitourinary, or metabolic disturbances * has known allergies, hypersensitivity, or intolerance to icotrokinra or its excipients * has other inflammatory diseases that might confound the evaluations of benefit of icotrokinra therapy, including but not limited to rheumatoid arthritis (ra), systemic lupus erythematosus, or lyme disease * participants with fibromyalgia or osteoarthritis symptoms that, in the investigator's opinion, would have potential to interfere with efficacy assessments
study of the covid-19 epidemic and socio-economic living conditions in france

Conditions: General Population

Summary: epicov is a population-based cohort which aims to provide national and regional estimates of seroprevalence of sars-cov-2 infection and analyse relations between living conditions and the dynamics of the epidemic in france. the study population is a random sample of individuals aged 15 years and older, excluding people living in residences for the elderly and living in jail. the participants are recruited from the french national tax register and is representative of the population living in france. home self-samples on dried blood spots (dbs) for igg and neutralizing antibodies detection were offered to a random national sub-sample of 12,114 in the 1st round of the epicov survey (may 2020) and to all respondents in the 2nd round (november 2020), including also serological testing for all members (≥ 6 years old) of household for 20% of index participants. a third round was perfomed in june-july 2021, without serological measurements. overall, 134,391 participants have been enrolled in first-round (may 2020). among them, 107 759 participated to the second round (november 2020) and 85 074 in third round (june 2021). the next wave is expected in march-april 2022.


Eligibility criteria:
inclusion criteria: * individuals aged 15 years or older * living on january 1, 2020, in mainland france or one of three overseas departments (martinique, guadeloupe and réunion island). exclusion criteria: * individuals living in prisons at the time of the study * people living in residential institutions for dependent elderly persons, as caregivers were not available during the epidemic period to help them with internet access or phone calls.
flash glucose monitoring targets in gestational diabetes

Conditions: Gestational Diabetes Mellitus (GDM)

Summary: the use of glucose monitoring sensors is already well-established in pregnant women with type 1 diabetes (t1d), where it has been proven to improve glycemic control and perinatal outcomes. however, it has not yet been sufficiently researched in the area of gestational diabetes (gdm). some smaller studies have shown a favorable effect on glycemic control, but no statistically significant differences were observed in reducing perinatal complications. a randomized, prospective study will include 200 pregnant women with gdm, treated at the diabetes outpatient clinic of the clinical department of endocrinology, diabetes, and metabolic diseases at the university medical centre ljubljana. participants will be divided into two groups. the first group will measure subcutaneous glucose using fsl in addition to self-monitoring of blood glucose (smbg) while fasting and 60 minutes after main meals at the same time intervals. in both groups, glycemic targets, maternal outcomes, and neonatal outcomes will be monitored. in the fsl + smbg group, sensor parameters for glycemic control will also be tracked.


Eligibility criteria:
inclusion criteria: 1. pregnant women treated at the diabetes outpatient clinic of the clinical department of endocrinology, diabetes, and metabolic diseases for gestational diabetes (gdm), 2. agreement with the study protocol and ability to follow the study protocol, 3. diagnosis of gdm established using the standard recommended ogtt method between the 24th and 28th weeks of pregnancy, 4. age between 18 and 40 years. exclusion criteria: 1. history of bariatric surgery, 2. treatment with systemic corticosteroids for more than 14 days prior to inclusion in the study, 3. multiple pregnancy, 4. hospitalization for psychiatric illness within the last year, 5. first visit to the diabetes outpatient clinic after the 34th week of gestation.

Keywords: gestational diabetes mellitus flash glucose monitoring pregnancy fgm
glycopyrrolate prophylaxis for prevention of bradyarrhythmia during laparoscopic cholecystectomy

Conditions: Bradyarrhythmia; Cardiac Arrest; Tachycardia; Asystole

Summary: the goal of this clinical trial is to evaluate the incidence of bradycardia during laparoscopic cholecystectomy. the main question\[s\] it aims to answer are: * does bradycardia really occurs during pneumoperitoneum/laparoscopic surgery? * if the patient get glycopyrrolate, does it really prevent pneumoperitoneum/laparoscopic surgery induced bradycardia?

the emergence of laparoscopic surgery has changed the way of approach for several organs. despite several advantages, laparoscopic surgery may result in serious complications due to the physiologic changes which occur during the procedure. the cardiovascular system is one of the most challenged systems of the human body during laparoscopy. the insufflation of gas into the peritoneal cavity can provoke arrhythmias. their incidence is as high as 14-27% of laparoscopies which is higher than in 'open' surgery. the life-threatening bradyarrhythmia (sinus bradycardia, nodal rhythm, atrio-ventricular dissociation and asystole) are frequently encountered during laparoscopic procedure which are due to a vagal-mediated cardiovascular reflex initiated by rapid stretching of the peritoneum at the beginning of peritoneal insufflation. there are studies addressing measures to prevent or control cardiovascular catastrophes during laparoscopic cholecystectomy. some studies suggest administration of anticholinergic agents especially glycopyrrolate and atropine for prevention of bradycardia during intra-abdominal laparoscopic surgeries. whereas some study suggests judicious use of atropine as it increases the risk of tachyarrhythmia. glycopyrrolate is a synthetic anticholinergic commonly used as a preoperative antimuscarinic agent to reduce salivary, tracheobronchial, and pharyngeal secretions, to reduce the volume and free acidity of gastric secretions, and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. hypothesis glycopyrrolate administration reduces the incidence of bradycardia during laparoscopic cholecystectomy. general objectives to evaluate the role of glycopyrrolate on prevention of bradyarrhythmia during laparoscopic cholecystectomy. specific objective 1. to evaluate the change in heart rate and rhythm at different time interval after pneumoperitoneum. 2. to evaluate the change in systolic, diastolic and mean arterial blood pressure at different time interval after pneumoperitoneum.

Eligibility criteria:
inclusion criteria: 1. adult patients of either sex aged 15-65 years 2. patient undergoing elective laparoscopic cholecystectomy 3. american society of anesthesiologists (asa) physical status i exclusion criteria: 1. patients with history of recent or past cardiac diseases 2. patients with pre-operative heart rate ≤60beats/min. 3. patients on cardiac medications 4. allergic to glycopyrrolate

Keywords: glycopyrrolate bradyarrhythmia laparoscopy pneumoperitoneum cardiac arrest
evaluation of fatigue severity, mood, and quality of life in post-polio syndrome

Conditions: Polio and Post-polio Syndrome; Fatigue; Polio

Summary: the aim of this study is to investigate the differences in the severity of fatigue, impact on quality of life, and mood between individuals with post-polio syndrome and healthy volunteer groups. additionally, the interrelationships of these parameters within the post-polio syndrome patient group will be examined. the goal is to raise awareness during the follow-up process for individuals with post-polio syndrome by questioning fatigue and mood symptoms, and to facilitate the implementation of necessary precautions.

our research is designed as a case-control study. 20 patients diagnosed with post-polio syndrome who present to the istanbul physical medicine and rehabilitation training and research hospital clinics and 20 healthy volunteers will be included in the study. the sociodemographic data of patients and volunteers, such as age, gender, height, weight, body mass index, education level, and occupation, will be recorded. the age at which polio was contracted, the time elapsed since polio, and any accompanying illnesses will be documented. additionally, if patients experience new symptoms such as pain, weakness, or fatigue, the severity of these symptoms will be assessed using the visual analog scale. the frequency of falls and the presence of fractures caused by falls, ambulation method, and devices used will be noted. muscle weakness in the extremities will be identified by applying the manual muscle test through physical examination. subsequently, the patient's current symptoms related to depression and anxiety will be evaluated using the hospital anxiety and depression scale (hads), fatigue level will be assessed using the fatigue severity scale (fss), and quality of life will be evaluated using the short form-36 (sf-36).

Eligibility criteria:
inclusion criteria: * individuals aged between 18 and 60 with post-polio syndrome. * healthy volunteers aged between 18 and 60 exclusion criteria: * fibromyalgia, * chronic fatigue syndrome, * presence of chronic decompensated cardiac, renal, and hepatic insufficiency, * known psychiatric disorders, * rheumatological diseases, * presence of other known neurological diseases, * use of medications aimed at improving physical performance or alleviating fatigue.

Keywords: poliomyelitis fatigue postpoliomyelitis syndrome